Van Well Daan sold $47K of SOPH

Van Well Daan (Chief Legal Officer) sold 6,168 shares of SOPHiA GENETICS SA (SOPH) at $7.63 on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Van Well Daan
Published Sep 14, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
high confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The disclosed sale is routine and small, offering little actionable insight for traders.

02

Market read

Minor insider sell with negligible market impact.

03

What to watch

Potential tax or liquidity needs of the insider, not company fundamentals.

Relevance 2/10Novelty 4/10Timing: filed 2026-09-14

Background

SEC Form 4 filings disclose insider transactions; they are primary sources for such events.

Company-level read

Ticker impact

$SOPHNeutralHigh confidence
Context

Chief Legal Officer Van Well Daan sold 6,168 shares for $47,089 via a 10b5-1 plan, reducing his stake to 338,884 shares.

Expected impact

Minimal downward pressure, likely negligible impact on share price.

Evidence & confidence

The transaction size is small relative to market cap and was pre‑arranged, suggesting no new information about the company.

Market effects

None; the sale does not signal broader sector trends.

Limited to Swiss biotech market, no broader regional effect.

Insignificant on a global scale.

Counterpoint

The sale could be interpreted as a lack of confidence, but the pre‑arranged nature diminishes this reading.

Key entities

  • SOPHiA GENETICS SA

    Swiss biotech firm listed on Nasdaq under SOPH.

  • Van Well Daan

    Chief Legal Officer of SOPHiA GENETICS.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September